Sign In
Buy DRTS
$11.79
-0.100 (-0.84%)
At Close: Jul 31, 2026
Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
04:02pm, Monday, 09'th Mar 2026
- Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and
HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT
08:51pm, Tuesday, 24'th Feb 2026
TOKYO--(BUSINESS WIRE)-- #cancer--Japan approves Alpha DaRT for head & neck cancer, becoming the first market outside Israel.
- Approval establishes first clinical authorization outside Israel and initiates post-market surveillance program - - First-in-kind technology delivers intra-tumoral alpha-emitting radiotherapeutics,
Lucid Diagnostics (NASDAQ:LUCD) & Alpha Tau Medical (NASDAQ:DRTS) Financial Survey
04:44am, Friday, 20'th Feb 2026
Alpha Tau Medical (NASDAQ: DRTS - Get Free Report) and Lucid Diagnostics (NASDAQ: LUCD - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast t
Alpha Tau Medical Ltd. (NASDAQ:DRTS) Sees Large Increase in Short Interest
02:55am, Sunday, 01'st Feb 2026
Alpha Tau Medical Ltd. (NASDAQ: DRTS - Get Free Report) saw a large growth in short interest in January. As of January 15th, there was short interest totaling 527,362 shares, a growth of 111.0% from t
Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead
09:00am, Thursday, 29'th Jan 2026
- Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ReSTART pivotal skin cancer trial as well as trials in can
New Strong Sell Stocks for January 27th
05:06am, Tuesday, 27'th Jan 2026
DRTS, MPC and NRXP have been added to the Zacks Rank #5 (Strong Sell) List on January 27th, 2026.
Alpha Tau Medical: Pancreatic, GBM, And Other Updates; Set Up For A Strong, Catalyst-Rich 2026
03:34am, Friday, 23'rd Jan 2026
Alpha Tau Medical is positioned for major catalysts in 2026, with its differentiated, tumor-agnostic Alpha DaRT technology gaining visibility and momentum. Pancreatic cancer and GBM readouts expected
New Strong Sell Stocks for January 20th
10:15am, Tuesday, 20'th Jan 2026
DAR, CADL and DRTS have been added to the Zacks Rank #5 (Strong Sell) List on January 20, 2026.
- Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first two patients - - Immune markers demonstrate immune system preservation n
- Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular submission framework granted to Alpha Tau by the FDA allows for streamlined review an
Why Did Alpha Tau Medical (DRTS) Shares Jump Over 25% In After-Hours Trading?
01:41am, Wednesday, 10'th Dec 2025
Alpha Tau Medical surged in after-hours trading after treating the first patient in its pilot study for recurrent glioblastoma with Alpha DaRT therapy.
- First patient in the world treated with Alpha DaRT ® in the brain – - According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cance
Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Thursday, 20'th Nov 2025
- Alpha DaRT pancreatic cancer p atient treatments underway in U.S. multi-center pilot study -
Alpha Tau Medical (DRTS) Expected to Announce Quarterly Earnings on Tuesday
01:20am, Sunday, 16'th Nov 2025
Alpha Tau Medical (NASDAQ: DRTS - Get Free Report) is projected to release its Q3 2025 results before the market opens on Tuesday, November 18th. Analysts expect the company to announce earnings of ($
